The court upheld the patent held by Japan’s Eisai for the ulcer treatment.
The US District Court for the Southern District of New York has upheld the US patent for ulcer treatment Aciphex (Rabeprazole Sodium) tablets, 20 mg, held by Japan’s Eisai Co. Ltd. (TSE: 4523). Teva said that it intends to appeal this decision immediately as well as the Court's decision granting to Eisai summary judgment of validity.
The US Food and Drug Administration (FDA) awarded Teva Abbreviated New Drug Application (ANDA) for a generic version of Aciphex with a 180-day marketing exclusivity.
Published by Globes [online], Israel business news - www.globes.co.il - on May 13, 2007
© Copyright of Globes Publisher Itonut (1983) Ltd. 2007